论文部分内容阅读
目的 观察干扰素 (IFNα 2b)联合胸腺肽治疗慢性乙型肝炎临床疗效。方法 干扰素5 0 0万IU ,皮下注射 ,隔日 1次 ,疗程 6个月。胸腺肽 2 0mg稀释后静脉注射或肌注 ,隔日 1次 ,疗程 3个月。以甘利欣 ,五味子制剂及垂盆草冲剂作对照 ,二者在性别、年龄、病程及病情轻重等方面皆具可比性。结果 HBVDNA和HBeAg的阴转率及总有效率分别为 75 % ,73 1% ,与对照组相比差异显著(P <0 0 1) ,在肝功能复常方面 ,治疗组与对照组相似。结论 干扰素对乙型肝炎病毒有明显抑制作用 ,尤其是HBVDNA和HBeAg同时阳性者 ,呈完全应答。
Objective To observe the clinical efficacy of interferon (IFNα 2b) combined with thymosin in the treatment of chronic hepatitis B patients. Interferon 500 000 IU, subcutaneous injection, every other day, treatment for 6 months. Thymosin 20mg diluted intravenous or intramuscular injection, every other day 1, course of treatment for 3 months. With Glycyrrhizin, Schisandra preparations and Saguet grass granules as a control, both in gender, age, duration and severity of disease are comparable. Results The negative conversion rate and total effective rate of HBVDNA and HBeAg were 75% and 73 1%, respectively, which were significantly different from those of the control group (P <0.01). The treatment group was similar to the control group in terms of liver function recovery. Conclusion Interferon has significant inhibitory effect on hepatitis B virus, especially HBVDNA and HBeAg-positive patients.